Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)
This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Jan 23, 2025 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Pfizer
- Interventions being studied
- Drug: Crizotinib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- histologically or cytologically proven diagnosis of malignancy other than NSCLC
- positive for translocation or inversion event involving the ALK gene locus
- positive for ALK amplification events
- positive for ALK activating point mutations
- mutations of amplifications involving the c-Met gene but not the ALK gene
- concurrent treatment on another therapeutic clinical trial
- prior therapy specifically directed against ALK
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Highlands Oncology GroupFayetteville, Arkansas
- Highlands Oncology GroupRogers, Arkansas
- Highland Oncology GroupSpringdale, Arkansas
- Washington University School of MedicineSt Louis, Missouri
- Comprehensive Cancer Centers of NevadaLas Vegas, Nevada
- OHSU Center for Health and Healing 2Portland, Oregon
- Oregon Health & Science UniversityPortland, Oregon
- Oregon Health and Science UniversityPortland, Oregon
- Greenville Health System, Institute for Translational Oncology ResearchGreenville, South Carolina
- Cancer Institute and Hospital, Chinese Academy of Medical SciencesBeijing, Chaoyang District
- SUN Yat-Sen University Cancer CenterGuangzhou, Guangdong
- Centro di Ricerca di Fase 1 ASST-MonzaMonza
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 23, 2025. Always confirm current availability with the study team.